Pfizer Inc. has decided to stop the development of its obesity pill, danuglipron, after safety concerns emerged from a clinical trial. This move comes as competition heats up with Novo Nordisk and Eli Lilly's successful weight-loss treatments.
A recent study reveals that Paxlovid, Pfizer's antiviral treatment for COVID-19, may not significantly reduce hospitalizations or deaths in vaccinated older adults. Researchers express surprise at the findings, urging caution in treatment decisions for this demographic.
